Reuters logo
a month ago
BRIEF-Reata Pharmaceuticals receives orphan drug designation for omaveloxolone for treatment of friedreich’s ataxia
June 22, 2017 / 11:17 AM / a month ago

BRIEF-Reata Pharmaceuticals receives orphan drug designation for omaveloxolone for treatment of friedreich’s ataxia

1 Min Read

June 22 (Reuters) - Reata Pharmaceuticals Inc:

* Reata Pharmaceuticals, Inc. receives orphan drug designation for omaveloxolone for the treatment of friedreich’s ataxia

* Reata Pharmaceuticals Inc - U.S. Food and Drug Administration granted orphan drug designation to omaveloxolone for treatment of friedreich's ataxia Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below